# LIGAND PHARMACEUTICALS INC (LGND) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from LIGAND PHARMACEUTICALS INC's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/LGND/mda/fy2025/): filed 2026-02-27; accession 0000886163-26-000006 (https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/lgnd-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/LGND/mda/fy2024/): filed 2025-02-28; accession 0000886163-25-000012 (https://www.sec.gov/Archives/edgar/data/886163/000088616325000012/lgnd-20241231.htm)
- [FY 2023 MD&A](/company/LGND/mda/fy2023/): filed 2024-02-29; accession 0000886163-24-000009 (https://www.sec.gov/Archives/edgar/data/886163/000088616324000009/lgnd-20231231.htm)
- [FY 2022 MD&A](/company/LGND/mda/fy2022/): filed 2023-02-28; accession 0000886163-23-000007 (https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/lgnd-20221231.htm)
- [FY 2021 MD&A](/company/LGND/mda/fy2021/): filed 2022-02-28; accession 0000886163-22-000030 (https://www.sec.gov/Archives/edgar/data/886163/000088616322000030/lgnd-20211231.htm)

Back to /company/LGND/